The Food and Drug Administration has approved two new ways to use a higher-dose, longer-acting version of Regeneron Pharmaceuticals’ Eylea, positioning the medicine to better compete in the eye ...

If approved, extended regimen would provide a longer treatment interval and additional dosing flexibility, alongside approved every 4- and 8-week dosing regimens TARRYTOWN, N.Y., June 29, 2022 ...

TARRYTOWN, N.Y., March 08, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced The Lancet published one-year results from the pivotal PULSAR and PHOTON trials for ...

Eylea (aflibercept) injections can cause both mild and serious side effects, though serious side effects are rare according to clinical trials. Mild side effects include eye floaters, redness, and ...

Approval based on the pivotal PULSAR and PHOTON trials in which EYLEA ® HD demonstrated clinically equivalent vision gains to EYLEA (aflibercept) Injection 2 mg that were maintained with fewer ...

TARRYTOWN, N.Y., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has approved EYLEA HD ® (aflibercept) ...

The cost of Eylea, an injectable medication for certain eye conditions, may vary based on your insurance coverage, treatment plan, and location of injections. Prior authorization may be required ...